China's independent research and development of chronic myeloid leukemia treatment drug approved for market

　　Medicine Network November 27th, China's State Drug Administration announced on the 26th, metasulfonate flumartinibinib (commodity name: Hausson Fu) listing registration application was recently approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph-CML) chronic adult patients The drug is an innovative drug with China's own intellectual property rights and has been approved for market through the priority review and approval process according to the introduction, the clinical characteristics of chronic myeloid leukemia is a significant increase in peripheral blood granulocytes, and the appearance of spleen significant lyumbleation The natural course of disease consists of three stages: chronic, accelerated and acute Data show that China's chronic myeloid leukemia accounts for more than 15% of all leukemia the National Drug Administration pointed out that methichynfluatine is a small molecule protein tyrosine kinase (PTK) inhibitor, by inhibiting Bcr-Abl tyrosine kinase activity, inhibited the Philadelphia chromosome-positive CML and some acute lymphocytic leukemia patients tumor cell proliferation, induced apoptosis The listing of methicillin flumartinib will provide new drug options for adult patients with chronic myeloid leukemia in China China has taken a series of measures in recent years to speed up the approval of reviews This includes speeding up the review of new drugs that are urgently needed for overseas clinical markets, implementing the system of implied licensing for clinical trials, and implementing the joint review and approval of original supplementary packages and preparations Among them, innovative drugs is one of the key points of drug review and approval reform in the drug supervision department In 2017, the drug regulatory department issued a letter specifying the priority review and approval of applications for , including the prevention and treatment of malignant tumors and rare diseases (Complete)